stockportfolio.pro
Medtronic plc (MDT)
Healthcare · Medical Devices · NYSE
Medtronic plc revenue & earnings — last 10 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29.71B | $29.95B | $30.56B | $28.91B | $30.12B | $31.69B | $31.23B | $32.36B | $33.54B | $36.33B |
| Gross profit | $20.42B | $20.90B | $21.40B | $19.49B | $19.63B | $21.54B | $20.51B | $21.15B | $21.91B | — |
| Net income | $4.03B | $3.10B | $4.63B | $4.79B | $3.61B | $5.04B | $3.76B | $3.68B | $4.66B | $4.80B |
| Net margin | 13.6% | 10.4% | 15.2% | 16.6% | 12.0% | 15.9% | 12.0% | 11.4% | 13.9% | 13.2% |
Source: Medtronic plc SEC filings (10-K). 14 years of history available in the interactive view.
What growth is priced into MDT stock?
At today's market cap of $105.25B, Medtronic plc is priced for free-cash-flow growth of about 7.9% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $5.18B from the FY ending 2025-04-30). For comparison, free cash flow actually grew -2.9%/yr over the last five fiscal years and revenue 3.8%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 14 years of Medtronic plc financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MDT in your portfolio →
Medtronic plc financial history by metric
About Medtronic plc
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
Medtronic plc — frequently asked questions
What is Medtronic plc's revenue?
Medtronic plc (MDT) reported revenue of $36.33B for fiscal year 2026, up 8.3% from the prior year, according to its SEC filings.
Is Medtronic plc profitable?
Yes. MDT earned net income of $4.80B in fiscal 2026, a net margin of 13.2%.
What is MDT's P/E ratio?
Medtronic plc trades at a price-to-earnings ratio of about 22.0 based on the latest data in our nightly-refreshed cache.
How fast is Medtronic plc growing?
MDT's revenue grew at roughly 3.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Medtronic plc have?
As of fiscal year 2026, MDT carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Medtronic plc's market cap?
Medtronic plc (MDT) has a market capitalization of about $105.25B, based on the latest data in our nightly-refreshed cache.
When does Medtronic plc's fiscal year end?
MDT's fiscal year ends in April. Its most recent annual filing covers the fiscal year ending 2026-04-30.
What growth is priced into MDT stock?
At today's market cap of $105.25B, Medtronic plc is priced for free-cash-flow growth of about 7.9% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $5.18B from the FY ending 2025-04-30). For comparison, free cash flow actually grew -2.9%/yr over the last five fiscal years and revenue 3.8%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Medtronic plc's official SEC filings (10-K and 10-Q), covering 14 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.